期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PPAR-γ激动剂对糖尿病患者心血管并发症的影响 被引量：1

下载PDF
导出
摘要 糖尿病发病率在逐年增加[1]。饮食和生活方式的改变在其发病中占有重要作用。糖尿病是缺血性心脑血管疾病的重要危险因素,其与许多大血管及微血管并发症密切相关,3/4的糖尿病患者死于心血管并发症。因此,糖尿病被国际学术组织定义为＂冠心病等危症＂[2]。尽管积极的血糖控制降低了如视网膜病变等微血管并发症,但其对大血管并发症降低不明显。STENO研究[3]表明,进行全面的危险因素控制,平均随访年限为7.8年,
作者 张明多 赵全明
机构地区 首都医科大学附属北京安贞医院 北京市心肺血管疾病研究所心内科
出处 《心肺血管病杂志》 CAS 2015年第2期144-146,共3页 Journal of Cardiovascular and Pulmonary Diseases
基金 北京市自然科学基金面上项目(7132078)
关键词 PPAR-Γ激动剂 糖尿病 心血管并发症
分类号 R543 [医药卫生—心血管疾病]
  • 相关文献

参考文献27

  • 1International Diabetes Federation.IDF Diabetes Atlas.5th edn.Brussels,Belgium:International Diabetes Federation,2011.
  • 2Rydén L,Grant PJ,Anker SD,et al.ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes,pre-diabetes,and cardiovascular diseases of the European Society of Cardiology(ESC)and developed in collaboration with the European Association for the Study of Diabetes(EASD).Eur Heart J,2013,34:3035-3087.
  • 3Gaede P,Vedel P,Larsen N,et al.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.N Engl J Med,2003,348:383-393.
  • 4Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med,2007,356:2457-2471.
  • 5Graham DJ,Ouellet-Hellstrom R,Macurdy TE,et al.Risk of acute myocardial infarction,stroke,heart failure,and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.JAMA,2010,304:411-418.
  • 6Loke YK,Kwok CS,Singh S.Comparative cardiovascular effects of thiazolidinediones:systematic review and meta-analysis of observational studies.BMJ,2011,342:d1309.
  • 7Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.Nature,1990,347:645-650.
  • 8Wilding JP.PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.Diabetes Obes Metab,2012,14:973-982.
  • 9Krishnaswami A,Ravi-Kumar S,Lewis JM.Thiazolidinediones:a 2010 perspective.Perm J,2010,14:64-72.
  • 10Deeg MA,Tan MH.Pioglitazone versus rosiglitazone:Effects on lipids,lipoproteins,and apolipoproteins in head-to-head randomized clinical studies.PPAR Res,2008,2008:520465.

二级参考文献16

  • 1赵全明,颜东,宋爱丽,王伟,时强,王绿娅,陈冬,方薇,武迎,许金鹏,陈欣,陈铁军,米树华,吕树铮.罗格列酮对ApoE基因敲除小鼠动脉粥样硬化的影响[J].中华心血管病杂志,2005,33(5):399-404. 被引量：15
  • 2Wang MH,Tafuri S.Modulation of PPARγ activity with pharmaceutical agents:treatment of insulin resistance and atherosclerosis.J Cel Bio,2003,89:38-47.
  • 3Marx N,Duez H,Fruchart JC,et al.Peroxisome proliferators activated receptors and atherogensis.Cir Res,2004,94:1168-1178.
  • 4Cyus T,Sung S,Zhao L,et al.Effect of low-dose aspirin on vascular inflammation plaque stability,and atherogenesis in low-density lipoprotein receptordeficient mice.Circulation,2002,106:1282-1287.
  • 5Collins AR,Meehan WP,Kintscher U,et al.Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.Atherioscler Thromb Vasc Biol,2001,21:365-371.
  • 6Ricote M,Li AC,Willson TM,et al.The peroxisome proliferator-activated receptor-[gamma] is a negative regulator of macrophage activation.Nature,1998,391:79-82.
  • 7Willa A,Ronald E.PPARγ and atherosclerosis effects on cell growth and movement.Arterioscler Thromb Vasc Biol,2001,21:1891-1910.
  • 8Goetze S,Xi XP,Kawano H,et al.PPARγ ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.J Cardio Pharma,1999,35:798-806.
  • 9Koshiyama H,Shimono D,Kuwamura N,et al.Rapid communication:inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.J Clin Endo Metab,2001,86:3452-3456.
  • 10doDios ST,Bruemmer D,Dilley RJ,et al.Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-[gamma] ligands toward internal mammary artery,radial artery,and saphenous vein smooth muscle cell proliferation.Circulation,2003,170:2548-2550.

共引文献3

同被引文献31

  • 1Pavoine C,Pecker F.Sphingomyelinases:their regulation and roles in cardiovascular pathophysiology.Cardiovasc Res,2009,82:175-183.
  • 2Hanada K.Serine palmitoyltransferase,a key enzyme of sphingolipid metabolism.Bba-Mol Cell Biol L,2003,1632:16-30.
  • 3Nilsson A,Duan RD.Absorption and lipoprotein transport of sphingomyelin.J Lipid Res,2006,47:154-171.
  • 4Ito M,Okino N,Tani Mi.New insight into the structure,reaction mechanism and biological functions of neutral ceramidase.Bba-Mol Cell Biol L,2014,1841:682-691.
  • 5Bielawska AE,Shapiro JP,Jiang L,et al.Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion.Am J Pathol,1997,151:1257-1263.
  • 6Der P,Cui J,Das DK.Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts.J Mol Cell Cardiol,2006,40:313-320.
  • 7Lecour S,Owira P,Opie LH.Ceramide-induced preconditioning involves reactive oxygen species.Life Sci,2006,78:1702-1706.
  • 8Liu SJ,Kennedy RH.Positive inotropic effect of ceramide in adult ventricular myocytes:mechanisms dissociated from its reduction in Ca2+influx.Am J Physiol-Heart C,2003,285:735-744.
  • 9Ren J,Relling DP.Leptin-induced suppression of cardiomyocyte contraction is amplified by ceramide.Peptides,2006,27:1415-1419.
  • 10Simon JN,Chowdhury SA,Warren CM,et al.Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation.Basic Res Cardiol,2014,109:445.

引证文献1

二级引证文献1

心肺血管病杂志
2015年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部